Debug Stats | ### Total Build Time: 25 ms 35.194 KB CONCEPT_NAME gt=3 ms Completed: 3 ms rowSize= 346 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 389 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=7 ms Completed: 7 ms rowSize= 9.691 KBCONCEPT_GENES gt=14 ms Completed: 14 ms rowSize= 23.557 KBCONCEPT_XREFS gt=1 ms Completed: 1 ms rowSize= 1.158 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (15)
Species: human : 15 | |
Human | CHEK2 | 11200 | checkpoint kinase 2 | FINDINGS: The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36). Analysis of familial male breast cancer for germline mutations in CHEK2. Our results indicate that CHEK2 1100delC variant does not substantially increase the risk of male breast cancer at the population level. CHEK2 1100delC is not a risk factor for male breast cancer population. We cannot exclude the fact that a small fraction of hereditary, family-positive male breast cancers could be attributable to CHEK2 mutations. We have previously shown that the1100delC variant of the cell-cycle-checkpoint kinase gene CHEK2, which is carried by approximately 1% of the population confers a two-fold increase in female breast cancer and a 10-fold increase in male breast cancer. To extend our knowledge on the role of CHEK2 in susceptibility to male breast cancer we have screened a series of 26 breast cancer cases with male representation for germline sequence variation in the CHEK2 gene. | Human | TFF1 | 7031 | trefoil factor 1 | CONCLUSIONS. Therefore, on the contrary to the situation in female breast cancer, pS2 activity failed to constitute a new prognostic parameter in male breast carcinomas. Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma. | Human | SYP | 6855 | synaptophysin | Synaptophysin expression was studied immunohistochemically in 109 female and in three male breast carcinomas. | Human | RNF4 | 6047 | ring finger protein 4 | Some AR ZFR point mutations observed in patients with partial androgen insensitivity syndrome or male breast cancer impair the interaction of AR with SNURF and also render AR refractory to the transcription-activating effect of SNURF. | Human | PRLR | 5618 | prolactin receptor | Prolactin receptor is significantly more expressed in male breast carcinoma than in gynaecomastia, and with different patterns of reactivity, suggesting a role for prolactin in male breast carcinogenesis | Human | PGC | 5225 | progastricsin (pepsinogen C) | Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma. Expression of pepsinogen C in gynecomastias and male breast carcinomas. This results demonstrate expression of pepsinogen C by gynecomastias and by a high percentage of male breast carcinomas and may indicate an important role of pepsinogen C in the pathophysiology of male breast diseases. | Human | MEN1 | 4221 | multiple endocrine neoplasia I | study describes a family with multiple cases of MEN1-associated cancers as well as pancreatic adenocarcinoma, ovarian cancer, and male breast cancer, in which we identified germline mutations in both MEN1 and BRCA2 | Human | LHCGR | 3973 | luteinizing hormone/choriogonadotropin receptor | demonstrated the presence of LH/hCG receptor mRNA and protein in normal male breast tissue obtained at autopsy and archival samples of benign gynecomastia and male breast carcinoma | Human | ESR1 | 2099 | estrogen receptor 1 | estrogen receptor-alpha may have a role in male breast cancer development [review] | Human | CYP17A1 | 1586 | cytochrome P450, family 17, subfamily A, polypeptide 1 | Title:A polymorphism in the CYP17 gene is associated with male breast cancer.|Association:Y|Conclusion:Not Found | Human | CDKN1B | 1027 | cyclin-dependent kinase inhibitor 1B (p27, Kip1) | P21Waf1 immunoreactivity is higher in male breast cancers compared with female breast cancers | Human | CDKN1A | 1026 | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | P27Kip1 immunoreactivity is higher in male breast cancers compared with female breast cancers | Human | BRCA2 | 675 | breast cancer 2, early onset | Click here to display 107 evidence detail records. | Human | BRCA1 | 672 | breast cancer 1, early onset | Founder BRCA1 mutation is associated with male breast cancer | Human | APOD | 347 | apolipoprotein D | Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia. |
|